Description
A prodrug of T-91825, a cephalosporin antibiotic; inhibits growth of S. pneumoniae, S. aureus, MSRA, E. coli, and K. pneumoniae in vitro (MICs = 0.008-2.0 mg/L); rapidly converted in vivo to T-91825 in rats and monkeys; has a bacteriostatic effect on S. pneumoniae, S. aureus, MSRA, E. coli, and K. pneumoniae in vivo when administered at doses ranging from 0.2-234 mg/kg per day; decreases the number of CFUs in a mouse model of thigh infection; exhibits a protective effect against systemic infection by clinical MRSA isolates in mice (ED50s = 1.08-4.81 mg/kg)
Formal name: 4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-methyl-pyridinium, monoacetate
Synonyms:
Molecular weight: 744.7
CAS: 400827-46-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Antibiotics|Cephalosporins||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Bacterial Diseases|MRSA||Research Area|Infectious Disease|Bacterial Diseases|Pneumonia
